Introduction
An estimated 35.6 million people are affected worldwide today by a mild to severe clinical dementia syndrome, associated with costs of approximately US$ 604 billion (World Alzheimer Report 2010, http://www.alz.org). The number of affected people is predicted to dramatically increase to 115 million by 2050 (World Alzheimer Report 2010, http://www.alz.org). Dementia of the Alzheimer's disease (AD) (see Glossary) type is the most frequent form of age-related dementia [1, 2] .
Clinically, initial progressive memory deficits that are eventually accompanied by more global cognitive and attention deficits are typical in AD dementia. Major pathologies in the brain associated with AD dementia have been identified, but the causes of such pathological changes are largely unknown. Causative factors include autosomal dominant inheritable mutations in the genes of presenilin
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Glossary
Amyloid-beta (Ab): the peptide that is the main component of amyloid deposits in forms of plaques in the brain, such as those detected by amyloid PET tracers. The Ab peptide is cleaved at different lengths of amino acid chains (isoforms) from the amyloid precursor protein (APP), and the isoform Ab 1-42 shows increased tendency to aggregate into plaques. Although plaques are abundant in the AD brain, the exact mechanism of neurotoxicity of Ab has not been established. Recent evidence suggests a role of the formation of soluble Ab oligomers in neurodegeneration [71] . Alzheimer's disease (AD) dementia: according to the traditional NINCDS-ADRDA criteria, AD dementia includes gradual onset of cognitive impairment in episodic memory and at least one other domain [14] . The recent NIA-AA revision of the diagnostic criteria does not make impairment in the episodic memory domain mandatory anymore, but requires impairment in amnestic or nonamnestic cognitive abilities [15] . Presence of impaired social functioning and instrumental activities of daily living is considered as the crucial difference for the clinical diagnosis of AD, as opposed to MCI. AD according to the Dubois criteria [11, 12] : presence of episodic memory impairment and abnormality on at least one of the core MRI-, PET-or CSFbased biomarkers of AD pathology are required. Encompasses both subjects with abnormal biomarkers who show clinical AD dementia and those who only show mild memory impairment (i.e. prodromal AD). Apolipoprotein E (ApoE) gene: the gene encodes, through three different alleles (e2, e3 and e4), three major isoforms of the ApoE protein, which are known to be involved in lipid metabolism. The ApoE e3/3 genotype is the most common form (prevalent in 50-70% of the population). The ApoE e4 allele, which only occurs in approximately 10-15% of the population, accounts for the majority of AD cases [108] and is also associated with increased risk of other forms of dementia, such as vascular dementia and Lewy body dementia [109] . ApoE e4 shows a gene dose effect in that presence of two ApoE e4 alleles is associated with a higher risk compared with a single ApoE e4 allele [109] . In AD, the ApoE e4 isoform has been associated with increased Ab deposition, although Ab-independent mechanisms of ApoE, such as reduced adult neurogenesis in the hippocampus or phosphorylation of the protein tau (associated with increased tau pathology in AD), have also been demonstrated [108] . Biomarker for AD: a quantifiable surrogate measure of brain pathologies underlying AD dementia [110] . Neuroimaging-derived measures have been proposed as core biomarkers for the early detection of AD. Other types of biomarker candidates that are considered as core biological indicators of AD pathology, include CSF-derived measures of Ab 1-42 , or the protein tau as a measure of neurofibrillary tangles (reviewed in [111] ). Clinical dementia rating (CDR): clinical rating scale used by the physician to assess performance in five different cognitive domains based on a semi-structured interview of both the patient and the informant [112] . The global CDR score ranges from 1 to 5, where a score of 0 means no cognitive impairment and a score of 5 corresponds to severe dementia. A score of 0.5 is often used in the diagnosis of MCI in clinical research studies [113] . 
